Abstract
Bladder cancer is the 9th most common cancer in the world and 70-80% of cases correspond to non-invasive bladder cancer (NMIBC). NMIBC treatment is surgical (tumor transurethral scraping) followed by adjuvant immunotherapy. In order to reduce the recurrence risk of the disease, immunotherapy is performed through intra-vesical applications of the tuberculosis vaccine BCG (Bacillus Calmette…